Arsenic and its combinations in cancer therapeutics

被引:11
作者
Prajapati, Vandana [1 ]
Kale, Raosaheb K. [1 ]
Singh, Rana P. [1 ,2 ]
机构
[1] Jawaharlal Nehru Univ, Sch Life Sci, Canc Biol Lab, New Delhi 110067, India
[2] Cent Univ Gujarat, Sch Life Sci, Gandhinagar, Gujarat, India
关键词
Sulfhydryl reagent; Fpg-sensitive sites; Nuclear factor-erythroid 2 p45-related factor 2; First-line treatment; Thiazolidinedione; Anthraquinones; Consolidation therapy; Maintenance therapy; Induction therapy;
D O I
10.4155/TDE.11.51
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Arsenic is a metalloid that is considered to be a paradox in terms of its role both as a carcinogen and as a therapeutic agent. Chronic exposure to arsenic in drinking water has been linked with the development of various pathological conditions including cancer. Nevertheless, the therapeutic potential of arsenic and its derivatives in a variety of diseases have been exploited in the past. However, its role and mechanism of action as a therapeutic agent still remain an active area of research and investigation. Our ongoing work also suggests varied responses in cancer cells exposed to lower versus higher concentrations of arsenic. Furthermore, the arsenic combinations with chemopreventive or anticancer agents have been observed to sensitize the cell for cell-cycle arrest and cell death. Here, we have provided the account of recent updates on the mechanism of action of arsenic and its derivatives that lead to various disorders, and its role as a therapeutic agent both as a single agent as well as in combination chemotherapy.
引用
收藏
页码:793 / 806
页数:14
相关论文
共 94 条
  • [1] Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients - A phase 2 trial
    Abou-Jawde, RM
    Reed, J
    Kelly, M
    Walker, E
    Andresen, S
    Baz, R
    Karam, MA
    Hussein, M
    [J]. MEDICAL ONCOLOGY, 2006, 23 (02) : 263 - 272
  • [2] Arsenic species that cause release of iron from ferritin and generation of activated oxygen
    Ahmad, S
    Kitchin, KT
    Cullen, WR
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 382 (02) : 195 - 202
  • [3] A Novel Nanoparticulate Formulation of Arsenic Trioxide with Enhanced Therapeutic Efficacy in a Murine Model of Breast Cancer
    Ahn, Richard W.
    Chen, Feng
    Chen, Haimei
    Stern, Stephan T.
    Clogston, Jeffrey D.
    Patri, Anil K.
    Raja, Meera R.
    Swindell, Elden P.
    Parimi, Vamsi
    Cryns, Vincent L.
    O'Halloran, Thomas V.
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (14) : 3607 - 3617
  • [4] Ahn WS, 2004, ONCOL REP, V12, P573
  • [5] [Anonymous], 2004, P NATL ACAD SCI USA, V101, P5328
  • [6] Ardalan B, CLIN CANC RES, V16
  • [7] Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia
    Aribi, Ahmed
    Kantarjian, Hagop M.
    Estey, Elihu H.
    Koller, Charles A.
    Thomas, Deborah A.
    Kornblau, Steven M.
    Faderl, Stefan H.
    Laddie, Nakia M.
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    [J]. CANCER, 2007, 109 (07) : 1355 - 1359
  • [8] Aronson S M, 1994, R I Med, V77, P233
  • [9] RIP kinase is involved in arsenic-induced apoptosis in multiple myeloma cells
    Bajenova, O
    Tang, B
    Pearse, R
    Feinman, R
    Childs, BH
    Michaeli, J
    [J]. APOPTOSIS, 2004, 9 (05) : 561 - 571
  • [10] Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells
    Barchowsky, A
    Dudek, EJ
    Treadwell, MD
    Wetterharn, KE
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 1996, 21 (06) : 783 - 790